The ARPA-H Engineering of Immune Cells Inside the Body (EMBODY) program aims to develop adaptable, low-cost therapies where cells in the body are given instructions to adjust their behavior to fight disease. 

Funding for awardees varies in amount and is contingent upon the recipient meeting aggressive milestones specific to their project.

The EMBODY performer teams are led by:  

• Global Life Science Solutions USA LLC (d.b.a Cytiva) in Marlborough, Mass. intends to advance a nanoparticle-based platform for in vivo gene editing to treat and eliminate gastrointestinal cancers.  
• ImmunoVec Inc. in Malibu, Calif. aims to use novel polymers to transport DNA cargo to immune cells to treat lupus.  
• Kernal Biologics, Inc. in Cambridge, Mass. intends to use a novel lipid nanoparticle-based platform to treat multiple sclerosis and blood cancers.  
• MarPam Pharma LLC in Landfall Village, Minn. seeks to advance a technology to target and kill HIV-infected T cells, make T cells resistant to HIV infection, and eliminate the virus from patients.
• Mucommune LLC in Durham, N.C. aims to deliver DNA with instructions to destroy cancer cells.
• STRM.BIO, Inc. in Cambridge, Mass. seeks to develop a novel delivery platform to transport therapeutic cargo to immune cells and treat autoimmune diseases.  
• Tessera Therapeutics, Inc. in Somerville, Mass. intends to conduct in vivo genetic engineering of T cells for the treatment of autoimmune diseases and cancer.